Latif Nasser

Whatever amount of time.

If now one person comes up with a health care cost, let's say it's for a month, that is $100,000 in that month, everybody else is in trouble.

There's no money left.

So they write this op-ed saying like prices are too high and the drugs are not that great.

And sort of the next like notable wave is there was this – there's this journal called Blood, which is really big to anybody that works in a community that has like –

How did we not know about this when we made the blood show?

Oh, I knew.

Just kept it in here.

Anyhow.

So, yes, there's a journal called Blood, which is basically like the journal for anybody that works in a field that has to do with blood.

And what happens is, like...

A hundred doctors get together and they co-sign an editorial, which basically says, we totally agree with everything you guys are saying, but we have an even bigger issue.

You know, with Zaltrap, you're talking about an expensive drug that maybe doesn't really do that much.

It's kind of easy, even though it had never been done before, to say, we're not going to use this.

What all of these doctors in the blood editorial are saying, what do you do when you have a really expensive drug, but it's really, really good?

It's like a drug you actually want to take.

Is that like a one day in the future we will face this kind of question?

No, that is like a now, today question.

The most important new medicine approved this year.

Everyone I talked to pointed me to this new drug.